Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

NCT02389621 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT02389621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02389621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Completed
Start date
June 15, 2015
Completion date
April 19, 2017
Enrollment
215 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic liver disease, thrombocytopenia